The aim of our study was to estimate plasma antioxidant activity as well as plasma nitric oxide (NO) and vascular endothelial growth factor levels in patients with metabolic syndrome compared with healthy participants.
Material and Methods
Fifty patients (24 women and 26 men, mean age 55.9 ± 11.8 years) with metabolic syndrome were compared with 25 healthy participants (12 women and 13 men, mean age 54.2 ± 12.8 years). Plasma total antioxidant activity and plasma levels of NO and VEGF were determined in all participants.
Results
In the patients with metabolic syndrome, plasma total antioxidant activity, nitric oxide, and vascular endothelial growth factor were significantly lower (P < .001) than that observed in healthy participants (3.2 ± 1.6 vs 6.4 ± 2.1 mM/L), (6.3 ± 2.2 vs 9.8 ± 2.7 μM/L), and 71.0 ± 16.9 vs 137.5 ± 12.6 pg/mL), respectively.
Conclusions
Decreased plasma total antioxidant activity, NO, and VEGF levels in patients with metabolic syndrome reflect significant endothelial dysfunction. This suggests that oxidation–reduction balance disorders might play an important role in this process
WangC.Y., LiaoJ.K.Current advances in statin treatment: from molecular mechanisms to clinical practice.Arch Med Sci.2007; 3: S91–S96.
2.
VermaS., AndersonT.J.Fundamentals of endothelial function for the clinical cardiologist.Circulation.2002; 105: 546–549.
3.
VitaJ.A., LoscalzoJ.Shouldering the risk burden: infection, atherosclerosis, and the vascular endothelium.Circulation.2002; 106: 164–166.
4.
PrasadA., ZhuJ., HalcoxJ.P., WaclawiwM.A., EpsteinS.E., QuyyumiA.A.Predisposition to atherosclerosis by infections: role of endothelial dysfunction.Circulation.2002; 106: 184–190.
5.
GuzikT.J., WestN.E., BlackE.Vascular superoxide production by NAD(P)H oxidase association with endothelial dysfunction and clinical risk factors.Circ Res.2000; 86: e85–e90.
6.
ThomasK.A.Vascular endothelial growth factor, a potent and selective angiogenic agent.J Biol Chem.1996; 271: 603–606.
7.
ZicheM., MorbidelliL., ChoudhuriR.Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis.J Clin Invest.1997; 99: 2625–2634.
DaskalopoulouS.S., MikhailidisD.P., ElisafM.Prevention and treatment of the metabolic syndrome.Angiology.2004; 55: 589–612.
10.
BenzieI.F., StrainJ.J.Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration.Methods Enzymol.1999; 299: 15–27.
11.
BartoszG., JanaszewskaA., ErtelD.Spectrophotometric determination of peroxyl radical-trapping capacity with ABAP and ABTS.Curr Topics Biophys.1998; 22: 11–13.
12.
KowalskiJ., BarylskiM., BanachM., GrycewiczJ., IrzmańskiR., PawlickiL.Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention.J Cardiovasc Pharmacol.2006; 48: 143–147.
13.
BanachM., MarkuszewskiL., ZastonkaJ., GrzegorczykJ., OkońskiP., JegierB.The role of inflammation in the pathogenesis of atherosclerosis.Przegl Epidemiol.2004; 58: 663–670.
14.
DodaniS., MarionL., SharmaG., ReedG.L., GeorgeV.The association of carotid intima media thickness with dysfunctional HDL in South Asians.Arch Med Sci.2008; 4: 40–46.
15.
HöyssäS., RontuR., KuukasjärviP.Aspirin and statin medication decreases the risk of myocardial infarction associated with LTA and NFKBIL1 polymorphisms.Cent Eur J Med.2006; 1: 237–249.
LantosJ., RothE., CzopfL., NemesJ., GalI.Monitoring of plasma total antioxidant status in different diseases.Acta Chir Hung.1997; 36: 188–189.
18.
DigiesiV., FiorilloC., CosmiL.Reactive oxygen species and antioxidant status in essential arterial hypertension during therapy with dihydropyridine calcium channel antagonists.Clin Ter.2000; 151: 15–18.
19.
RisauW.Mechanisms of angiogenesis.Nature.1997; 386: 671–674.
20.
FerraraN.Role of vascular endothelial growth factor in the regulation of angiogenesis.Kidney Int.1999; 56: 794–814.
21.
DulakJ., JozkowiczA.Nitric oxide in vascular endothelial growth factor synthesis and signaling.Circulation.2001; 104: E48–E49.
GuptaK., KshirsagarS., LiW.VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling.Exp Cell Res.1999; 247: 495–504.
24.
ForsytheJ.A., JiangR.H., IyerN.V.Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.Mol Cell Biol.1996; 16: 4604–4613.
25.
CarmelietP., DorY., HerbertJ.M.Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis.Nature.1998; 394: 485–490.
26.
MuroharaT., AsaharaT., SilverM.Nitric oxide synthase modulates angiogenesis in response to tissue ischemia.J Clin Invest.1998; 101: 2567–2578.
27.
DulakJ., JozkowiczA., Dembińska-KiećA.Nitric oxide induces the synthesis of vascular endothelial growth factor in rat vascular smooth muscle cells.Arterioscler Thromb Vasc Biol.2000; 20: 659–666.
28.
HiasaK., IshibashiM., OhtaniK.Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization.Circulation.2004; 109: 2454–2461.
29.
TingH.H., TimimiF.K., BolesK.S., CreagerS.J., GanzP., CreagerM.A.Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus.J Clin Invest.1996; 97: 22–28.
30.
OkońskiP., BanachM., RyszJ.L-arginine improves hemodynamic function and coronary flow in an experimental model of ischemia-reperfusion injury.Ann Transplant.2006; 11: 28–34.
31.
Dubois-RandeJ.L., ZelinskyR., RoudotF.Effects of infusion of L-arginine into the left anterior descending coronary artery on acetylcholine-induced vasoconstriction of human atheromatous coronary arteries.Am J Cardiol.1992; 70: 1269–1275.
32.
GochA., BanachM., MikhailidisD.P., GochJ.H.Endothelial dysfunction in patients with non-complicated and complicated hypertension.Clin Exp Hypertens.2008; 30: IN PRESS.
33.
StamlerJ.S., LohE., RoddyM.A., CurrieK.E., CreagerM.A.Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans.Circulation.1994; 89: 2035–2040.
34.
GryglewskiR.J., PalmerR.M., MoncadaS.Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor.Nature.1986; 320: 454–456.
35.
Vasquez-VivarJ., KalyanaramanB., MartasekP.Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors.Proc Natl Acad Sci U S A.1998; 95: 9220–9225.
36.
RyszJ., BanachM., StolarekR.A.TNF-alfa priming effect on polymorphonuclear leukocytes reactive oxygen species generation and adhesion molecule expression in hemodialyzed patients.Arch Immunol Ther Exp.2006; 54: 209–215.
37.
PolusM., PolusA., PawlusE.Oxidized low density lipoprotein (ox-LDL) inhibits inducible nitric oxide synthase (iNOS) gene induction in rat vascular smooth muscle cells (VSMC).Acta Angiol.1997; 1: 13–19.
38.
KowalskiJ., BanachM., BarylskiM., IrzmanskiR., PawlickiL.Carvedilol modifies antioxidant status of patients with stable angina.Cell Mol Biol Lett.2008; 13: 230–239.
